Member Info for Laura2022

Stockraiser

The current £1.4mln market value should be at least x 5 if not X 10

Amazing by PYC CEO , who lest we forget , on one of lowest salaries on AIM

And PYC revenues versus market cap one of most undervalued on AIM

Dr Peter Sargent, CEO of Physiomics, commented:

"I am thrilled that the changes we've made here at Physiomics are starting to have a positive effect on the Company's performance. Not only will we exceed expectations for FY25, but we've started FY26 with record levels of contracted revenue yet to be recognised and are generating significant momentum across our key growth initiatives.

Based on unaudited end of year accounts for FY25, the Company is projecting to finish the year with a Total Income of £834k and Loss after Tax of £419k, both metrics being ahead of expectations for FY25. When compared to the year ended 30 June 2024 (FY24), these unaudited numbers would represent an increase in Total Income of approximately 46% and a reduction in Loss after Tax of approximately 31%, reflecting the positive growth trajectory of the business and effective cost management.

Delayed from an hour before close

11-Jul-25

16:19:19

25.457

65,138

You can buy on all brokers

Ghost

He has gone under 10+ different names since Christmas and LSE have...eventually ..banned each one for lying and disrupting

William

Aka TommyD25

Aka Santa2024

Aka Mainman25

Aka Neil777

All.previous banned names

Most recent was mid June Mainman25

Sharmeen Roy, PharmD, BCPS

Chief Strategy & Science Officer @ DoseMeRx | Precision Medicine

18h

I’ve seen what happens when dosing isn’t individualized, supportive care turns reactive, and we’re left managing consequences.

With Physiomics' models now in DoseMeRx, MIPD extends the same individualized framework across both chemo and supportive therapies.

This shifts us from drug-specific adjustments to true regimen-level care—proactive, not reactive.

A step toward preventing adverse events, not chasing them!

Good perception ODD

Buys as sells again above 0.47

Https://investors.finseta.com/shareholder-centre/significant-shareholders/

Massively overdone

Bought this morning

Morning Tremch

More has been progressed and delivered in the last 12mths under Dr PS than at any other stage in last 4 years sets up PYC nicely for rest of 2025

2phevs

Excellent link , thank you

Furthermore, due to complimentary capabilities across the DoseMe and Physiomics businesses, both parties have identified the opportunities to collaborate on the development of new dosing software tools beyond GCSF and docetaxel.

Osd

There is a good article from Ralph which explains how the PYC platforms can link to the DoseMeRx one

Osd

As you've probably seen its simply not worth trying to reason with people whose sole existence seems to be to troll and disrupt YET cant actually offer any investment suggestions not actually invest

Osd

Very good post, I think you've answered your own questions about this person

One look at the last 12mths-18mths of their posts would probably confirm your thoughts so

I filtered this person 5mths ago

Everything above 0 46p last hour or so is a buybut shown as sells

Brighty

Good to see you, not seen you for a year

Burt

We've already got the main and admitted to trader out, plus those last week too

Onwards

Thankyou Ralph

Is that new please ?